XNCR  valuation analysis

Name: Xencor, Inc
Description: Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. (more)
Industry: Biotechnology
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: May 05, 2021
Market cap: $1.90B (1073rd)
Sales(TTM): $124.27M (1390th)
Earnings(TTM): -$50.07M (1224th)

FFER: 1.60*
Actual price: $32.63
* Earnings were reported Aug 02, 2021 but we do not have the financials for this quarter. This is likely because the company has not yet released them. However, it might also be a problem with data quality. Regardless, you should take the FFER above with a grain of salt until we get updated financials.

Prices as of EOD 2021-07-15
Price & Estimates
Sales & Earnings history (TTM)
No notables found through heuristics.
Earnings / MarketCap
Xencor, Inc
"Biotechnology" industry
Sales / MarketCap
Xencor, Inc
"Biotechnology" industry
Book / MarketCap
Xencor, Inc
"Biotechnology" industry
Equity / Assets
Xencor, Inc
"Biotechnology" industry